期刊文献+

共无定形药物——新型单相无定形二元体系 被引量:9

Pharmaceutical Coamorphous——A Newly Defined Single-Phase Amorphous Binary System
原文传递
导出
摘要 共无定形药物是活性药物成分与其他小分子固体物质(药物或辅料)结合形成的具有单一玻璃化转变温度的单相无定形二元体系。它作为一种新的药物固体形态,可能改善药物的溶解度、溶出速率、稳定性及生物利用度等理化性质,已成为药物研发的一种新途径。本文主要对共无定形药物的定义、形成机理、制备方法、分析鉴别方法、物理化学稳定性以及溶解度和溶出速率进行综述,并对共无定形与固体分散体和共晶的比较进行了概述。 Pharmaceutical coamorphous, a kind of single-phase amorphous binary system, is formed between an active pharmaceutical ingredient (API1) and another solid small molecular compound (API2 or excipient). As a newly defined solid form, pharmaceutical coamorphous has been one new approach for drug research and development, due to its great potential in the improvement of solubility, dissolution, stability or even bioavailability. Several methods can be used for the preparation of coamorphous drugs, including quench- cooling, solvent evaporation and milling/cryo-milling. In this paper, the definition, preparation, physicochemical characterization and formation mechanism of pharmaceutical coamorphous are addressed. The comparison between coamorphous and solid dispersion or cocrystals is also presented.
出处 《化学进展》 SCIE CAS CSCD 北大核心 2014年第2期478-486,共9页 Progress in Chemistry
基金 国家"重大新药创制"科技重大专项项目(No.2011ZX09201-101-02) "中央高校基本科研业务费专项资金"(No.JKP2011006)资助~~
关键词 共无定形 单相二元体系 形成机理 玻璃化转变温度 稳定性 coamorphous single-phase binary system formation mechanism glass transition temperature stability
  • 相关文献

参考文献37

  • 1Radtke M. New Drugs, 2001, 3: 62.
  • 2Hu J, Johnston K P, Williams R O. Int. J. Pharm. , 2004, 271 : 145.
  • 3马坤,高静,马磊.药物的共晶与盐[J].中国药科大学学报,2012,43(5):475-480. 被引量:15
  • 4高缘,祖卉,张建军.药物共晶研究进展[J].化学进展,2010,22(5):829-836. 被引量:56
  • 5Lara-ochoa F, Espinosa-p6rez G. Supramol. Chem. , 2007, 19: 553.
  • 6Morissette S L, A|marsson O, Peterson M L, Remenar J F, Read M J, Lemmo A V, Ellis S, Cima M J, Gardner C R. Adv. Drug Deliver. Rev. , 2004, 56: 275.
  • 7Lu Q, Zografi G. Pharm. Res., 1998, 15: 1202.
  • 8Lbmann K, Laitinen R, Grohganz H, Gordon K C, Strachan C, Rades T. Mol. Pharm. , 2011, 8: 1919.
  • 9Descamps M, Willart J F, Dudognon E, Caron V. Journal of Pharmaceutical Science, 2007, 96: 1398.
  • 10Hoppu P, Jouppila K, Rantanen J, Schantz S, Juppo A M. J. Pharm. Pharmaeol. , 2007, 59: 373.

二级参考文献92

  • 1Walsh R B, Padgett C W, Metrangolo P, et al. Crystal Growth & Design, 2001, 1(2) : 165-175.
  • 2Oswald I, Motherwell W, Parsons S. Acta Crystallographica Section E: Structure Reports Online, 2004, 60 ( 11 ) : 1967- 1969.
  • 3Almarsson Z M. Chemical Communications, 2004, 1889-1896.
  • 4Caira M. Mol. Pharma. , 2007, 4:310-316.
  • 5Aaker~y C. Acta Crystaltographica Section B: Structural Science, 1997, 53 (4): 569-586.
  • 6Blagden N, De Matas M, Gavan P, et al. Advanced Drug Delivery Reviews, 2007, 59(7): 617-630.
  • 7Huang C, Leiserow L, Schmidt G. J. Chem. Soc. , 1973, 2: 503 -508.
  • 8Remenar J, Morissette S, Peterson M, et al. Journal of the American Chemical Society, 2003, 125 (28) : 8456-8457.
  • 9Childs S, Chyall L, Dunlap J, et al. Journal of the American Chemical Society, 2004, 126(41): 13335-13342.
  • 10Vishweshwar P, Mcmahon J, Peterson M, et al. Chemical Communications, 2005, 4601-4603.

共引文献67

同被引文献39

引证文献9

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部